REGENXBIO Inc. RGNX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, REGENXBIO Inc. reported revenue across 7 products and services; the largest, Zolgensma And Itvisma Royalties, was $83.2M (+2.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Zolgensma And Itvisma Royalties$83.2Mshare n/a+2.1% yoy
- Zolgensma Royalties$82.5Mshare n/a+1.3% yoy
- Nippon Shinyaku Licenses$72.9Mshare n/ano prior
- Total Service Revenue$14.2Mshare n/a+936.1% yoy
- Nippon Shinyaku Services$11.8Mshare n/ano prior
- Other Service Revenue$2.35Mshare n/a+71.9% yoy
- Itvisma Royalties$641Kshare n/ano prior
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Abb Vie Development Milestone$100Mshare n/ano prior
- Total Service Revenue$4.18Mshare n/a+44.4% yoy
- Zolgensma And Itvisma Royalties$3.84Mshare n/a-79.2% yoy
- Nippon Shinyaku Services$3.72Mshare n/a+36.8% yoy
- Itvisma Royalties$2.09Mshare n/ano prior
- Zolgensma Royalties$1.75Mshare n/a-90.5% yoy
- +1 more member in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.